Approved indications: Vitrase is approved as an adjuvant to (1) subcutaneous fluid administration for hydration (hypodermoclysis), (2) increase dispersion and absorption of other injected drugs given by subcutaneous, intramuscular, or other local routes, and (3) improve resorption of radiopaque contrast agents during subcutaneous urography when intravenous access is difficult or not possible.

Common off-label uses (with evidence mainly from clinical experience and smaller studies):

• Management of extravasation of certain intravenous medications and solutions to help disperse fluid and reduce local tissue injury.
• Enhancement of regional or ophthalmic anesthetic blocks to speed onset and improve spread of local anesthetics.
• Facilitation of some subcutaneous infusions (such as immunoglobulin or other biologics), though recombinant human hyaluronidase products are used more commonly for this purpose.

Efficacy expectations: When injected with or just before other drugs or fluids, Vitrase acts within minutes, leading to faster spread and absorption under the skin, more rapid and comfortable hydration with hypodermoclysis, and more uniform contrast enhancement for subcutaneous urography; its effect in the tissue is temporary, generally lasting only a few hours.

Comparison to similar drugs: Vitrase (ovine-derived hyaluronidase) provides similar clinical benefits and dosing ranges to other hyaluronidase injections (such as Amphadase and Hylenex); recombinant human products may carry a slightly lower risk of immune reactions, but overall efficacy in enhancing fluid and drug absorption is comparable.

General administration: Vitrase is supplied as a single-dose hyaluronidase injection and is given by trained healthcare professionals by subcutaneous, intramuscular, or other local tissue routes, but not intravenously; the solution should be clear and colorless, and aseptic technique is required.

Subcutaneous fluid administration (hypodermoclysis): For adults and most children, 200 units are injected subcutaneously into the infusion line or under the skin just before or during clysis, typically facilitating absorption of about 1,000 mL or more of isotonic fluid; total volume and infusion rate are adjusted to age, weight, and comorbidities, with lower daily volumes and slower rates used in infants and especially in neonates.

Enhancing dispersion and absorption of injected drugs: To help other subcutaneous or intramuscular injections spread and be absorbed, 50–300 units of Vitrase (most often 150 units) are mixed with the drug solution or injected immediately before the drug at the same site, following compatibility references and avoiding known incompatible drugs.

Subcutaneous urography: When intravenous contrast cannot be used, typically 75 units are injected subcutaneously over each scapula (total 150 units) followed by injection of the radiopaque contrast medium at the same sites, especially in infants and small children.

Special dosing instructions: Vitrase should not be mixed in the same syringe or bag with drugs known to be incompatible (such as furosemide, certain benzodiazepines, or phenytoin), and it should not be used to enhance absorption of dopamine or other strong alpha-agonist vasopressors. After mixing with other solutions, it should be used within the time frame and conditions specified by the prescriber, generally within a few hours.

Missed dose and overdose guidance: Because Vitrase is usually given in a clinic or infusion setting as a single or intermittent adjunct dose, patients should contact their healthcare provider to reschedule if an appointment or planned dose is missed, rather than trying to obtain extra doses on their own. In case of suspected overdose or unexpected severe reactions (such as marked swelling, rapid spread of another drug’s effects, or signs of allergy), emergency medical care or poison control advice should be sought immediately.

Common side effects:

• Local injection-site reactions such as redness, swelling, tenderness, itching, warmth, bruising, or mild pain, which are usually mild and short-lived.
• Swelling or edema in the area when used with subcutaneous fluids, and occasionally mild nausea, flushing, sweating, or a fast heartbeat due to faster absorption of the co-administered drug.

Serious or rare adverse effects needing immediate medical attention:

• Allergic reactions, including hives, generalized rash, facial or tongue swelling, trouble breathing, chest tightness, or feeling faint, which may signal an anaphylactic reaction.
• Spread of a localized infection or worsening redness, warmth, and pain if injected into or near infected or acutely inflamed tissue.
• Ocular corneal damage if applied directly to the cornea or used improperly in the eye, presenting as severe eye pain, vision changes, or marked redness.
• Enhanced systemic toxicity of some co-administered drugs because of more rapid absorption.

Warnings and precautions: Vitrase should not be injected into or around infected or acutely inflamed areas and should not be used to reduce swelling from insect bites or stings. It is not intended for intravenous use, because the enzyme is rapidly inactivated and may increase risk without benefit. Use cautiously for subcutaneous fluid administration in people with heart failure, severe kidney impairment, or conditions prone to fluid overload, and monitor closely in neonates, infants, and older adults. In pregnancy and breastfeeding, human data are limited; because systemic exposure is low after local injection, clinicians usually reserve use for situations where the expected benefit clearly outweighs potential risk.

Relative safety compared with alternatives: Hyaluronidase products in general are well tolerated, with local reactions and fluid-related swelling the most common problems; ovine-derived Vitrase may carry a slightly higher risk of hypersensitivity than recombinant human hyaluronidase, but serious reactions remain very rare overall.

Reporting and staying updated: Patients should report any bothersome or severe side effects to their healthcare provider and may report suspected adverse reactions to the U.S. Food and Drug Administration (FDA) MedWatch program by phone or online; updated safety communications are available through the FDA and the manufacturer.

Drug and solution interactions: Vitrase should not be mixed in the same syringe or infusion container with certain drugs that are physically or chemically incompatible, including furosemide, some benzodiazepines, and phenytoin, and it should not be used to enhance the absorption and dispersion of dopamine or other alpha-agonist vasopressors. When combined with local anesthetics, it can speed onset and shorten duration of numbness and may increase the chance of systemic anesthetic side effects.

Effects of other medicines on Vitrase activity: Large doses of salicylates, corticosteroids, adrenocorticotropic hormone (ACTH), estrogens, or antihistamines can reduce hyaluronidase activity, sometimes requiring higher amounts of Vitrase to achieve the same dispersing effect.

Foods, alcohol, and nonprescription products: No specific food interactions are known, and alcohol does not directly interact with Vitrase, but alcohol or sedating medicines may worsen dizziness or blood-pressure changes caused by rapidly absorbed co-administered drugs; patients should always tell their clinician about all prescription medicines, over-the-counter products, and supplements they use.

Key precautions:

• Do not inject into or around infected or acutely inflamed skin, and do not use it to treat swelling from insect bites or stings.
• Avoid intravenous administration because the enzyme is rapidly inactivated and may increase risk without benefit.
• Use carefully in patients with heart failure, kidney impairment, or other conditions that make fluid overload dangerous when Vitrase is used to facilitate subcutaneous fluids.
• Consider prior allergies to animal proteins or previous reactions to hyaluronidase; skin testing may be performed before use in high-risk individuals.
• During pregnancy or breastfeeding, use only when clearly needed after discussion of risks and benefits, as systemic exposure is low but human data are limited.

Monitoring needs: When Vitrase is used, clinicians typically monitor the injection site for excessive swelling, redness, or signs of infection, observe for allergic reactions, and, when it is used with subcutaneous fluids, follow fluid balance, weight, and vital signs; additional tests (such as blood work or ECGs) are guided by the underlying illness and the other drugs being administered.

Q: What is Vitrase and why is it given with other injections?
A: Vitrase is a hyaluronidase enzyme injection that temporarily loosens the tissue barrier under the skin so that fluids and other injected medicines can spread and be absorbed more easily, improving hydration, imaging, or the effectiveness of the main drug.

Q: How long does Vitrase stay active in my body?
A: Its effect in the tissue is short-lived, usually lasting only a few hours, and the enzyme is then broken down by the body like natural enzymes, so it does not remain active long term.

Q: Can Vitrase be used to treat swelling from an insect bite or sting?
A: No, Vitrase should not be used for insect bites or stings because it can spread venom and infection in the tissues; other treatments such as cold packs, antihistamines, or epinephrine (for severe reactions) are preferred.

Q: Is Vitrase safe during pregnancy or breastfeeding?
A: There are limited data in pregnant and breastfeeding people, but because the medicine is given locally and systemic exposure is low, clinicians may use it when clearly needed after weighing the benefits and potential risks for the parent and baby.

Q: What might I feel when Vitrase is injected?
A: Many people notice only mild, brief stinging, burning, or swelling at the injection site, which usually settles quickly, but you should seek urgent care if you develop a rash, trouble breathing, or severe pain.

Q: Can I inject Vitrase myself at home?
A: Vitrase is usually prepared and given by trained healthcare professionals in a clinic or infusion setting, and it should only be used at home in specialized programs where you have been specifically trained and instructed by your care team.

Storage: Keep vials in their original carton in a refrigerator (typically 36°F–46°F / 2°C–8°C), protect from light, do not freeze, and do not use the solution if it is cloudy, discolored, or contains particles.

Before use: Once Vitrase is drawn up or mixed with another solution, it should be used promptly as directed by the healthcare provider and not saved for later use.

Disposal: Single-dose vials, used needles, and syringes should be discarded immediately after one use in an FDA-cleared sharps container; when the container is full, follow local or pharmacy guidance for disposal, and keep all supplies out of reach of children and pets.